Axil Brands vs cbdMD
AXIL and YCBD side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXIL and YCBD compare
Axil Brands is the larger company, worth 8.4 times as much as cbdMD ($35.4M against $4.2M).
Axil Brands grew revenue faster over the last twelve months (10.3% versus 10.0% for cbdMD).
Axil Brands keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with −13.8% at cbdMD.
Axil Brands scores higher on the StockData Score (19 against 10 for cbdMD), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXIL | YCBD |
|---|---|---|
| Size and price | ||
| Market cap | $35.4M | $4.2M |
| Share price | $5.19 | $0.374 |
| Change, 1 year | 5.5% | −51.7% |
| Change, 5 years | 72.7% | −99.9% |
| Beta (5Y) | 0.50 | 0.61 |
| Employees | 13 | 42 |
| StockData Score | ||
| Total score | 19 (better) | 10 |
| Valuation score | 6 (better) | 3 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 15.3× | – |
| P/S | 1.2× | 0.2× (better) |
| P/B | 2.6× | 0.5× (better) |
| EV/EBITDA | 8.5× | – |
| P/FCF | 8.1× | – |
| PEG | 0.31 | – |
| FCF yield | 12.3% (better) | −57.5% |
| Fair value | $12.61 | $2.22 |
| Margin of safety | 58.8% | 83.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.3% (better) | 10.0% |
| Revenue growth, 5Y average | 80.0% (better) | −14.5% |
| Net income growth (TTM) | 114% | – |
| EPS growth (TTM) | 113% | – |
| Profitability | ||
| Gross margin | 72.4% (better) | 57.7% |
| Operating margin | 10.0% (better) | −13.9% |
| Net margin | 9.3% (better) | −13.8% |
| FCF margin | 14.5% (better) | −11.5% |
| Return on equity | 23.3% (better) | −40.3% |
| Return on invested capital | 43.2% (better) | −41.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.31 (better) | 2.50 |
| Altman Z-score | 7.63 (better) | −17.57 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.6% | 8.2% |
| Held by insiders | 69.6% | 34.6% |
| Insider net buying, 12 months | – | −$1.3M |
| Short interest, % of float | 0.48% | 6.6% |
Go deeper
- AXIL stock overview
- AXIL income statement
- AXIL valuation and score
- YCBD stock overview
- YCBD income statement
- YCBD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.